Aldoxorubicin may be safe, effective for advanced soft-tissue sarcoma
the ONA take:
Single-agent aldoxorubicin, a novel albumin-binding prodrug of doxorubicin, showed superior efficacy over doxorubicin and manageable adverse effects in patients with advanced soft-tissue sarcoma, a new study published online ahead of print in JAMA Oncology has shown.
For the international, multicenter, open-label, phase 2b study, researchers enrolled 126 patients with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma. Participants were randomly assigned 2:1 to receive aldoxorubicin 350 mg/m2 or doxorubicin 75 mg/m2 administered intravenously once every 3 weeks for up to six cycles.
Results showed that median progression-free survival was significantly improved with aldoxorubicin compared with doxorubicin. In addition, 6-month progression-free survival rates and tumor response rates were significantly improved with aldoxorubicin.
In regard to safety, no acute cardiotoxic effects were observed with either treatment, but left ventricular ejection fraction less than 50% occurred in 3 of 40 patients who received doxorubicin. Grade 3 or 4 neutropenia occurred more frequently in the aldoxorubicin group.
The findings suggest that further investigation of aldoxorubicin therapy in advanced soft-tissue sarcoma is warranted.
Single-agent aldoxorubicinshowed superior efficacy over doxorubicin and manageable adverse effects in advanced soft-tissue sarcoma.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|